期刊
INTERNATIONAL JOURNAL OF ONCOLOGY
卷 55, 期 3, 页码 697-707出版社
SPANDIDOS PUBL LTD
DOI: 10.3892/ijo.2019.4838
关键词
liver kinase b1; fibrinogen-like 1; lung adenocarcinoma; epithelial-mesenchymal transition; angiogenesis
类别
资金
- National Science Foundation of China [81602009, 81672288]
- Shandong University [SDU-KI-2019-16]
- Karolinska Institute [SDU-KI-2019-16]
Liver kinase b1 (LKB1) is a tumor suppressor, and the inactivated mutation frequency of LKB1 in lung adenocarcinoma is 20%. The present study aimed to explore potential novel biomarkers in LKB1 mutant lung adenocarcinoma. Gene expression data from lung adenocarcinoma patients were downloaded from The Cancer Genome Atlas and the Gene Expression Omnibus databases. R software was used to analyze the gene expression profiles. Reverse transcription-quantitative PCR (RT-qPCR), western blot and immunohistochemistry (IHC) analyses were used to examine gene expression and function. Gene function was further explored via gene set enrichment analysis. A colony formation assay was used to evaluate cell proliferation. A wound-healing assay and immunofluorescence analysis were used to evaluate cell migration and epithelial-mesenchymal transition (EMT), respectively. Wound healing assay, immunofluorescence, western blot, RT-qPCR and IHC results for EMT-associated markers demonstrated that a loss of fibrinogen-like 1 (FGL1) induced EMT in LKB1 mutant lung adenocarcinoma. RT-qPCR and IHC analyses of angiogenesis-related markers revealed that loss of FGL1 promoted angiogenesis in LKB1 mutant lung adenocarcinoma. Overall, the present results demonstrated that loss of FGL1 induced EMT and angiogenesis in LKB1 mutant lung adenocarcinoma. FGL1 may be a novel biomarker to indicate EMT and angiogenesis in patients with LKB1 mutant lung adenocarcinoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据